These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

971 related articles for article (PubMed ID: 19614715)

  • 1. Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates.
    López-Cerero L; Picón E; Morillo C; Hernández JR; Docobo F; Pachón J; Rodríguez-Baño J; Pascual A
    Clin Microbiol Infect; 2010 Feb; 16(2):132-6. PubMed ID: 19614715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inoculum effect on the efficacies of amoxicillin-clavulanate, piperacillin-tazobactam, and imipenem against extended-spectrum β-lactamase (ESBL)-producing and non-ESBL-producing Escherichia coli in an experimental murine sepsis model.
    Docobo-Pérez F; López-Cerero L; López-Rojas R; Egea P; Domínguez-Herrera J; Rodríguez-Baño J; Pascual A; Pachón J
    Antimicrob Agents Chemother; 2013 May; 57(5):2109-13. PubMed ID: 23439636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Susceptibility of Escherichia coli isolates with TEM-1 beta-lactamase to combinations of BRL42715, tazobactam or clavulanate with piperacillin or amoxycillin .
    Livermore DM; Seetulsingh P
    J Antimicrob Chemother; 1991 Jun; 27(6):761-7. PubMed ID: 1669013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Susceptibilities of ESBL-producing Enterobacteriaceae to ertapenem, meropenem and piperacillin-tazobactam with and without clavulanic acid.
    Raveh D; Yinnon AM; Broide E; Rudensky B
    Chemotherapy; 2007; 53(3):185-9. PubMed ID: 17347564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-ESBL producing Klebsiella pneumoniae.
    Burgess DS; Hall RG
    Diagn Microbiol Infect Dis; 2004 May; 49(1):41-6. PubMed ID: 15135499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro efficiency of the piperacillin/tazobactam combination against inhibitor-resistant TEM- and complex mutant TEM-producing clinical strains of Escherichia coli.
    Robin F; Krebs M; Delmas J; Gibold L; Mirande C; Bonnet R
    J Antimicrob Chemother; 2011 May; 66(5):1052-6. PubMed ID: 21393211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibacterial susceptibility of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
    Bishara J; Livne G; Ashkenazi S; Levy I; Pitlik S; Ofir O; Lev B; Samra Z
    Isr Med Assoc J; 2005 May; 7(5):298-301. PubMed ID: 15909461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae.
    Thomson KS; Moland ES
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3548-54. PubMed ID: 11709338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimicrobial susceptibility of well-characterised multiresistant CTX-M-producing Escherichia coli: failure of automated systems to detect resistance to piperacillin/tazobactam.
    Pitout JD; Le P; Church DL; Gregson DB; Laupland KB
    Int J Antimicrob Agents; 2008 Oct; 32(4):333-8. PubMed ID: 18701262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Killing of Escherichia coli by beta-lactams at different inocula.
    Tam VH; Ledesma KR; Chang KT; Wang TY; Quinn JP
    Diagn Microbiol Infect Dis; 2009 Jun; 64(2):166-71. PubMed ID: 19304437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Occurrence of ESBL & Amp-C beta-lactamases & susceptibility to newer antimicrobial agents in complicated UTI.
    Taneja N; Rao P; Arora J; Dogra A
    Indian J Med Res; 2008 Jan; 127(1):85-8. PubMed ID: 18316858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative activities of cefepime and piperacillin/tazobactam tested against a global collection of Escherichia coli and Klebsiella spp. with an ESBL phenotype.
    Sader HS; Hsiung A; Fritsche TR; Jones RN
    Diagn Microbiol Infect Dis; 2007 Mar; 57(3):341-4. PubMed ID: 17141461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors determining resistance to beta-lactam combined with beta-lactamase inhibitors in Escherichia coli.
    Reguera JA; Baquero F; Pérez-Díaz JC; Martínez JL
    J Antimicrob Chemother; 1991 May; 27(5):569-75. PubMed ID: 1653204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Behaviour of beta-lactamase-positive and -negative Staphylococcus aureus isolates in susceptibility tests with piperacillin/tazobactam and other beta-lactam/beta-lactamase inhibitor combinations.
    Bonfiglio G; Livermore DM
    J Antimicrob Chemother; 1993 Sep; 32(3):431-44. PubMed ID: 8262865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of the in vivo pharmacodynamic profile of cefepime against extended-spectrum-beta-lactamase-producing Escherichia coli at various inocula.
    Maglio D; Ong C; Banevicius MA; Geng Q; Nightingale CH; Nicolau DP
    Antimicrob Agents Chemother; 2004 Jun; 48(6):1941-7. PubMed ID: 15155182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo activities of piperacillin-tazobactam and meropenem at different inoculum sizes of ESBL-producing Klebsiella pneumoniae.
    Harada Y; Morinaga Y; Kaku N; Nakamura S; Uno N; Hasegawa H; Izumikawa K; Kohno S; Yanagihara K
    Clin Microbiol Infect; 2014 Nov; 20(11):O831-9. PubMed ID: 24813594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of temocillin against extended spectrum beta-lactamase-producing Escherichia coli.
    Rodriguez-Villalobos H; Malaviolle V; Frankard J; de Mendonça R; Nonhoff C; Struelens MJ
    J Antimicrob Chemother; 2006 Apr; 57(4):771-4. PubMed ID: 16501056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended-spectrum cephalosporins and the inoculum effect in tests with CTX-M-type extended-spectrum β-lactamase-producing Escherichia coli: potential clinical implications of the revised CLSI interpretive criteria.
    Kang CI; Cha MK; Kim SH; Wi YM; Chung DR; Peck KR; Lee NY; Song JH
    Int J Antimicrob Agents; 2014 May; 43(5):456-9. PubMed ID: 24690213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative in vitro activities of amoxicillin-clavulanate, ampicillin-sulbactam and piperacillin-tazobactam against strains of Escherichia coli and proteus mirabilis harbouring known beta-lactamases.
    Gatermann S; Marre R
    Infection; 1991; 19(2):106-9. PubMed ID: 1646771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibiotic policy and prescribing strategies for therapy of extended-spectrum beta-lactamase-producing Enterobacteriaceae: the role of piperacillin-tazobactam.
    Peterson LR
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():181-4. PubMed ID: 18154544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.